John McGonigle Selected Research

GSK598809

8/2017	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.
4/2017	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.
1/2017	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John McGonigle Research Topics

Disease

7	Alcoholism (Alcohol Abuse) 01/2019 - 09/2015
2	Substance-Related Disorders (Drug Abuse) 01/2018 - 04/2017
2	Opioid-Related Disorders (Opiate Addiction) 01/2018 - 11/2017
1	Obesity 01/2021
1	COVID-19 01/2021
1	Fatty Liver 01/2020
1	Liver Neoplasms (Liver Cancer) 01/2020
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 01/2019
1	Hepatitis 01/2018
1	Treatment-Resistant Depressive Disorder 10/2017
1	Hallucinations (Hallucination) 04/2016
1	Alzheimer Disease (Alzheimer's Disease) 12/2015

Drug/Important Bio-Agent (IBA)

5	Pharmaceutical PreparationsIBA 01/2018 - 09/2015
3	Naltrexone (ReVia)FDA LinkGeneric 01/2019 - 11/2017
3	GSK598809IBA 08/2017 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2015
2	Narcotic Antagonists (Opioid Antagonists)IBA 01/2018 - 01/2017
1	MetalsIBA 01/2020
1	Nitrofurantoin (Macrodantin)FDA LinkGeneric 01/2018
1	Psilocybin (Psilocibin)IBA 10/2017
1	Serotonin Receptor Agonists (Serotonin Receptor Agonist)IBA 10/2017
1	nalmefene (Revex)FDA Link 01/2017
1	Opioid Receptors (Opioid Receptor)IBA 01/2017
1	Hallucinogens (Psychedelics)IBA 04/2016

Therapy/Procedure

1	Therapeutics 01/2020
1	Secondary Prevention 01/2018
1	Aftercare (After-Treatment) 10/2017